A quick genetic screen may be able to tell doctors which lung cancer patients will benefit from new, targeted cancer drugs that have dramatic effects but only in a few people, U.S. researchers said on Thursday. They found a specific DNA mutation in people who were virtually cured of their cancer by a new drug called Iressa, made by AstraZeneca Plc .
